Profile data is unavailable for this security.
About the company
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has seven marketed prescription pharmaceutical products and over 25 programs in development at the Company, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six market areas, including oncology, rare diseases and gene therapy. Its dermatology products include Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Exelderm and Luxamend. Its late stage product candidates include Cosibelimab (anti-PD-L1 antibody), DFD-29 (modified release oral minocycline for the treatment of rosacea), CUTX-101 (copper histidinate injection for Menkes disease), IV Tramadol, Olafertinib (also known as CK-101, EGFR inhibitor for EGFR mutation-positive NSCLC), CAEL-101 (monoclonal antibody for AL amyloidosis) and Triplex (cytomegalovirus (CMV) vaccine).
- Revenue in USD (TTM)85.11m
- Net income in USD-62.86m
- Incorporated2006
- Employees186.00
- LocationFortress Biotech Inc1111 KANE CONCOURSE, SUITE 301BAY HARBOR ISLANDS 33154United StatesUSA
- Phone+1 (781) 652-4500
- Fax+1 (781) 652-4545
- Websitehttps://www.fortressbiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KALA BIO Inc | 0.00 | -39.55m | 33.93m | 43.00 | -- | 3.22 | -- | -- | -15.15 | -15.15 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -63.15 | -57.83 | -76.71 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -12.26 | 0.8382 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
| Cyclo Therapeutics Inc | 1.13m | -19.39m | 36.05m | 8.00 | -- | 59.10 | -- | 32.01 | -1.03 | -1.03 | 0.0557 | 0.0213 | 0.2001 | 0.4155 | 11.12 | 140,806.30 | -344.43 | -132.22 | -17,225.46 | -215.17 | 91.02 | 90.37 | -1,721.63 | -1,114.04 | 0.968 | -- | 0.00 | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
| Qilian International Holding Group Ltd | 46.47m | -7.78m | 36.18m | 298.00 | -- | 0.8455 | -- | 0.7785 | -1.09 | -1.09 | 6.50 | 5.98 | 0.8027 | 6.45 | 33.30 | 155,944.60 | -14.03 | 2.71 | -16.84 | 3.86 | 3.77 | 11.66 | -17.48 | 2.72 | 4.43 | -0.4812 | 0.0107 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| Natural Alternatives International, Inc. | 120.20m | -3.31m | 36.52m | 317.00 | -- | 0.4343 | 27.22 | 0.3039 | -0.5646 | -0.5646 | 20.53 | 13.56 | 0.8091 | 3.63 | 12.77 | 379,183.00 | -2.23 | 4.90 | -2.56 | 5.93 | 8.85 | 15.98 | -2.75 | 3.80 | 2.44 | -2.71 | 0.0996 | 0.00 | -9.91 | 3.06 | -76.46 | -20.74 | 27.08 | -- |
| Aadi Bioscience Inc | 23.84m | -68.83m | 38.55m | 75.00 | -- | 0.4262 | -- | 1.62 | -2.55 | -2.55 | 0.8848 | 3.68 | 0.1692 | 0.6021 | 4.54 | 267,865.20 | -48.86 | -50.25 | -56.39 | -56.15 | 87.70 | -- | -288.72 | -473.97 | 4.86 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
| Incannex Healthcare Inc | -100.00bn | -100.00bn | 40.22m | -- | -- | 2.84 | -- | -- | -- | -- | -- | 0.8907 | -- | -- | -- | -- | -- | -54.94 | -- | -59.47 | -- | -- | -- | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
| Fortress Biotech Inc | 85.11m | -62.86m | 45.33m | 186.00 | -- | 1.70 | -- | 0.5326 | -6.65 | -6.65 | 7.96 | 1.19 | 0.3976 | 2.27 | 4.55 | 457,602.20 | -64.47 | -52.50 | -107.85 | -99.46 | 68.25 | 63.17 | -162.17 | -236.94 | 1.21 | -10.18 | 1.07 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
| Lexaria Bioscience Corp | 411.01k | -4.85m | 45.53m | 5.00 | -- | 4.50 | -- | 110.78 | -0.4455 | -0.4455 | 0.0408 | 0.6403 | 0.0539 | -- | 2.16 | 82,202.00 | -63.85 | -95.67 | -65.93 | -96.58 | 98.83 | 76.98 | -1,185.15 | -1,612.76 | -- | -64.96 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| Bright Green Corp | 0.00 | -11.46m | 46.32m | 5.00 | -- | 4.17 | -- | -- | -0.0631 | -0.0631 | 0.00 | 0.0584 | 0.00 | -- | -- | 0.00 | -56.05 | -- | -84.87 | -- | -- | -- | -- | -- | -- | -18,125.84 | 0.0289 | -- | -- | -- | 52.54 | -- | -- | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 48.00m | 1.00 | -- | 0.268 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| Odonate Inc | 0.00 | -102.07m | 50.02m | 137.00 | -- | 1,844.41 | -- | -- | -13.59 | -13.59 | 0.00 | 9.27 | 0.00 | -- | -- | 0.00 | -66.98 | -58.36 | -83.00 | -65.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | -- | -- |
| Ocuphire Pharma Inc | 19.01m | -11.30m | 53.14m | 14.00 | -- | 1.12 | -- | 2.80 | -0.4867 | -0.4867 | 0.8366 | 1.84 | 0.391 | -- | 4.52 | 1,357,929.00 | -23.24 | -58.31 | -25.89 | -65.94 | -- | -- | -59.44 | -137.92 | -- | -7.80 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| United-Guardian, Inc. | 11.57m | 2.75m | 54.30m | 25.00 | 19.74 | 4.86 | 19.02 | 4.69 | 0.5987 | 0.5987 | 2.52 | 2.43 | 0.926 | 3.17 | 6.40 | 462,790.80 | 22.02 | 29.84 | 25.94 | 34.39 | 48.64 | 55.31 | 23.78 | 28.79 | 5.99 | -- | 0.00 | 97.37 | -14.28 | -4.14 | 0.4616 | -9.92 | 17.19 | -19.73 |
| Immix Biopharma Inc | 0.00 | -18.21m | 57.58m | 14.00 | -- | 2.06 | -- | -- | -0.9263 | -0.9263 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -77.50 | -- | -90.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
Data as of Jul 22 2024. Currency figures normalised to Fortress Biotech Inc's reporting currency: US Dollar USD
12.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rosalind Advisors, Inc.as of 30 Jun 2024 | 607.80k | 2.98% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 477.30k | 2.34% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 292.06k | 1.43% |
| Nantahala Capital Management LLCas of 31 Mar 2024 | 278.15k | 1.36% |
| Shikiar Asset Management, Inc.as of 30 Jun 2024 | 225.97k | 1.11% |
| B. Riley Wealth Advisors, Inc.as of 31 Mar 2024 | 144.70k | 0.71% |
| PVG Asset Management Corp.as of 31 Dec 2023 | 131.49k | 0.64% |
| Geode Capital Management LLCas of 31 Mar 2024 | 113.32k | 0.56% |
| GSA Capital Partners LLPas of 31 Mar 2024 | 107.28k | 0.53% |
| Corient Private Wealth LLCas of 31 Mar 2024 | 105.33k | 0.52% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
